CPC A61K 39/39 (2013.01) [A61K 35/17 (2013.01); A61K 38/177 (2013.01); A61K 38/19 (2013.01); A61K 38/20 (2013.01); A61K 38/21 (2013.01); A61K 39/085 (2013.01); A61K 39/385 (2013.01); A61K 39/44 (2013.01); C12N 5/0637 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/55516 (2013.01); A61K 2039/55522 (2013.01); A61K 2039/55527 (2013.01); A61K 2039/55533 (2013.01); A61K 2039/57 (2013.01)] | 3 Claims |
1. A method of treating a patient with a solid tumor, the method comprising:
inducing the production of endogenous IL-12 in the patient, wherein the endogenous IL-12 is induced by administering a composition comprising activated allogeneic Th1 cells to the patient, wherein the Th1 cells are activated by cross-linking CD3 and CD28;
ablating all or portion of the solid tumor in the patient to generate tissue necrosis along with intratumoral administration of the activated allogeneic Th1 cells;
measuring the level of endogenous IL-12 in the patient; and
readministering the composition until endogenous IL-12 in the plasma of the patient is at least about 5000 pg/ml.
|